Sarepta Therapeutic (SRPT) PT Raised to $102 at Baird

September 19, 2016 12:21 PM EDT
Get Alerts SRPT Hot Sheet
Price: $32.66 +1.43%

Rating Summary:
    16 Buy, 9 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade SRPT Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

(Updated - September 19, 2016 12:23 PM EDT)

Baird reiterated an Outperform rating and raised its price target on Sarepta Therapeutic (NASDAQ: SRPT) to $102.00 (from $23.00) following FDA approval of eteplirsen.

Analyst Brian Skorney commented, "After months of delays, requests for additional data, and a slew of other DMD rejections, the FDA handed Sarepta a victory this morning. Eteplirsen, branded as EXONDYS 51, has been approved under the accelerated pathway, with a broad label. As a result of the approval and receipt of a potentially lucrative priority review voucher, we are increasing our price target to $102, which now takes into account increased probabilities of commercial expansion into other exons."

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $28.15 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst PT Change, Hot Comments, Trader Talk

Related Entities

Robert W Baird

Add Your Comment